063160 — CKD Bio Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩128bn
- KR₩271bn
- KR₩160bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | — | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 4,564 | 1,533 | 3,535 | 12,724 | 3,700 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 43,160 | 25,342 | 29,907 | 27,471 | 34,108 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 80,042 | 88,382 | 104,342 | 123,464 | 111,769 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 150,832 | 191,189 | 191,153 | 181,509 | 172,509 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 233,348 | 283,463 | 298,540 | 312,591 | 293,785 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 45,024 | 46,114 | 44,311 | 81,591 | 98,618 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 74,885 | 114,715 | 137,049 | 164,792 | 170,761 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 158,463 | 168,748 | 161,491 | 147,799 | 123,024 |
Total Liabilities & Shareholders' Equity | 233,348 | 283,463 | 298,540 | 312,591 | 293,785 |
Total Common Shares Outstanding |